



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 4, 2021

Nathan Jorgensen  
Chief Financial Officer  
Vor Biopharma Inc.  
100 Cambridgepark Drive  
Suite 400  
Cambridge, Massachusetts 02140

**Re: Vor Biopharma Inc.  
Registration Statement on Form S-1  
Exhibit Nos. 10.1, 10.2 and 10.3  
Filed: January 15, 2021  
File No.: 333-252175**

Dear Mr. Jorgensen:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance